Athersys (ATHX) Director Jane Wasman Appointed Board Chair Oct 2, 2023 05:06PM
Athersys Director Jane Wasman Appointed Board Chair Oct 2, 2023 05:04PM
Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer Sep 12, 2022 07:00AM
Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer Sep 12, 2022 07:00AM
Rigel to Present at the H.C. Wainwright 24th Annual Global Investment Conference Sep 6, 2022 08:30AM


Aug 2, 2022 04:02PM Rigel Reports Second Quarter 2022 Financial Results and Provides Business Update
Aug 2, 2022 04:01PM Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Jul 26, 2022 08:30AM Rigel Announces Conference Call and Webcast to Report Second Quarter 2022 Financial Results and Business Update
Jun 8, 2022 07:02AM Rigel Pharma (RIGL) Reports Phase 3 FORWARD Trial of Fostamatinib Did Not Achieve Statistical Significance
Jun 8, 2022 07:00AM Rigel Announces Top-line Results from FORWARD Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia
May 3, 2022 04:01PM Rigel Reports First Quarter 2022 Financial Results and Provides Business Update
Apr 26, 2022 08:30AM Rigel Announces Conference Call and Webcast to Report First Quarter 2022 Financial Results and Business Update
Apr 8, 2022 07:30AM Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Mar 8, 2022 08:05AM Rigel Pharma (RIGL) Reports Publication of Data from Phase 2 Clinical Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Mar 8, 2022 08:05AM Rigel Announces Publication of Data from Phase 2 Clinical Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia in the American Journal of Hematology
Mar 1, 2022 04:01PM Rigel Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Feb 22, 2022 08:30AM Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2021 Financial Results and Business Update
Jan 10, 2022 04:15PM Rigel to Present at the J.P. Morgan Healthcare Conference
Jan 10, 2022 08:41AM Rigel Pharma (RIGL) sees TAVALISSE preliminary 2021 net product sales of approximately $63.0 million
Jan 10, 2022 08:40AM Rigel Pharmaceuticals Provides Business Update
Jan 7, 2022 07:00PM Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Dec 21, 2021 08:30AM Rigel Pharma (RIGL) Announces Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan
Dec 21, 2021 08:30AM Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of Chronic Immune Thrombocytopenia
Dec 16, 2021 09:02AM Rigel Pharma (RIGL) Appoints Kamil Ali-Jackson to its Board
Dec 16, 2021 09:00AM Rigel Appoints Kamil Ali-Jackson to Board of Directors
Nov 15, 2021 08:38AM Rigel Pharma (RIGL) will reduce its workforce by 16%
Nov 15, 2021 08:30AM Rigel Sharpens Focus on Its Advanced Portfolio Opportunities
Nov 9, 2021 07:30AM Rigel to Participate in Two Upcoming Investor Conferences
Nov 2, 2021 04:01PM Rigel Reports Third Quarter 2021 Financial Results and Provides Business Update
Oct 26, 2021 07:30AM Rigel Announces Conference Call and Webcast to Report Third Quarter 2021 Financial Results and Business Update
Oct 8, 2021 04:50PM Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Sep 2, 2021 07:30AM Rigel to Participate in Three Upcoming Investor Conferences
Sep 1, 2021 07:32AM Rigel Pharma (RIGL) Announces Phase 2 Trial Results of Fostamatinib in Hospitalized COVID-19 Patients Published
Sep 1, 2021 07:30AM Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases
Aug 13, 2021 07:33AM Rigel Pharma (RIGL) informed by FDA clinical data submitted from Phase 2 trial of fostamatinib to treat hospitalized patients suffering from COVID-19 are insufficient for EUA at this time
Aug 13, 2021 07:30AM Rigel Pharmaceuticals Provides Update on COVID-19 Program
Aug 3, 2021 04:01PM Rigel Reports Second Quarter 2021 Financial Results and Provides Business Update
Jul 27, 2021 07:30AM Rigel Announces Conference Call and Webcast to Report Second Quarter 2021 Financial Results and Business Update
Jul 14, 2021 07:30AM New TAVALISSE® Data Analyses To Be Presented at International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress
Jun 29, 2021 07:30AM Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial